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B 4.6
Management Algorithm for Intermittent Claudication
B 4.6.1
Basic Strategy Algorithm for Intermittent Claudication
I History and physical examination J
Ankle:brachial pressure index
Confirm PAD with intermittent claudication
IIAssess cardiovascular + Assess disability" Irisk factors symptom severity
I I
Initial evaluation: Treadmill andlor:
• Haemoglobin • SF-36 questionnaire
• Serum creatinine • WIQ questionnaire
• Smoking history I
• Lipid profile I I I• Hypertension
• Diabetes IMild symptoms-I Moderate symptoms-« Severe
Not disabled Disabled symptoms-
I I
Disabled
Special investigations: I• Hypercoagulability screen
• Homocysteine level
• Lp(a) Encourage supervised walking exercise program
• Other Consider pharmacotherapy
I.Modify risk factors I I I• Antiplatelet therapy IContinue I
I
Successful Unsuccessful I
F-36 =MedicalOutcomesShort Form 36 Questionnaire outcome outcome
Q =Walking ImpairmentQuestionnaire IVR = pulse volumerecording
= velocitywaveformanalysis Locate lesion using:
=magneticresonanceangiography
• Segmental limb pressuresC = Joint National Commission
• PVRorVWFAIC =haemoglobinAlC
• Duplex scanniogDL = low-densityli~prrtein • AngiographyL =high-density ltOprotein Continue
·MRADisability as defined y the individualpatient noninvasive
measures I
Endovascular or I
surgical therapy
S
WIp
VWF
MRA
IN
Hb
L
lID
•
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B 4.6.2
Complete Management Algorithm for Intermittent Claudication
I, Historyand ph)'sieal cxamirution
Ankle.brachia!pressure index
ConfirmPAD with intermittentclaudication
IIAssess cardiovascular + Assessdisability· Irisk factors symptomseventy
I I
Initial evaluation: ITreadmill and/or: I
• Haemoglobin • SF-36questionnaire
• Serum creatinine • \~lQ questionnaire
• Smoking history I
• Lipid profile I I I• Hypertension
• Diabetes IMild symptorns-s- I Moderale symptcms-« I I Severe I
Not disabled Disabled symptorns->
Special investigations: I I DiS;bled• Hyperccagulability screen
-
• Homocysteine level
· l p(a) Encourage supervised walking exercise program
-Other Consider pharmacotherapy
I.Modify risk factors I I I• Ar.tipb.tc:lcttherapy IContinue I
I I
I I ISuccessful I IUnsuccessful I
111~l""homoc)'st.incmia II H)'!"?fCoagulable.andI outcome outcomeIDiabetes treatmentI II H?c on treatment I
· HbAIC< 7.0% ? olate or B.. artet;a1 thrombosis • 0 lowmc VI guidelines I-Anticoagulate
Locatelesion using:
Smokin.scessation liBd goals • Segmental limb pressures
-Behaviourmodification
-L l cholesterol < 100 mgldl · PVRor VWF
-Nicotine replacement
-Rednce ~l)'ceride • Duplex scanning
·Bupropion ·~IID cholesterol • Angiography
' MRA
6 ~ MedicalOutcomes Short Form 36 Questionnaire I~Walking Impairment Questionnaire I I= pulse volume recording
= velocity waveform analysis I Unacceptable risk II Acceptable risk I
= magneticresonance angiography I I for intervention for interve ntion= Joint NationalCommissionIC = haemoglobin AIC I= low-<lensity Iin;:protein
= high-<lenSIty ,~protein I,Continue,I IEndovesculer or Isability as defiried y the individualpatient noninvasive
measures surgical therapy
SF-3
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ECONOMIC ASPECTS OF INTERMITTENT
CLAUDICATION
Cos t data on the diagnosis or treatment of claudica-
tion appear to be very scarce in the medical and the
economic liter ature. This is partl y because an alyses
of c1audicants ha ve presented resul ts on the global
cost of the d isea se (including all types of patients)
or instead of the Fontaine class ification ha ve us ed
som e other grouping method that renders interp re-
tation of the results difficult. In other cases, the
results concerned small numbers of patients with
minimal description of the sampling methods and
little externa l validity. In the results presented later
in this document and also in Economic Aspects of
Acute Limb Ischaemia and Economic Aspects of
Cr itical Limb Isch aem ia, costs are in US dollars with
the European Euro in brackets, and local currencies
were converted based on th e Organisation for
Economic Cooperation and Development (OECD)
purchasing power parity index. The year of the
study is indicated.
B 5.1.1
Diagnostic Strategies
When assessing diagnostic strategies for patients with
claudication, the economic analysis can focus on (1)
the most effective diagnostic strategy for a given indi-
vidual, (2) the screening strategy for the population at
large, or (3) a subset of those presenting risk factors
(eg, smoking or cardiac disease). The investigations
concern risk factors that could benefit from secondary
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